Activation of immune response in disease dynamics via controlled drug scheduling

IEEE Transactions on Automation Science and Engineering

Volumn 6, Issue 2, 2009, Pages 248-255

  Chang, Hyeygjeon ^a   Astolfi, Alessandro ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Biological systems; Disease dynamics; Human immunodeficiency virus acquired immune deficiency syndrome (HIV AIDS) models; Long term nonprogressor

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROMES; ANTIRETROVIRAL DRUGS; BOOSTING MECHANISMS; CLINICAL METHODS; CONTROL METHODOLOGIES; CONTROL METHODS; CONTROL PURPOSE; DISEASE DYNAMICS; DISEASE MODELS; DRUG SCHEDULING; DYNAMIC PROCESS; EQUILIBRIUM CONDITIONS; HIV MODELS; HUMAN IMMUNO DEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNE DEFICIENCY SYNDROME (HIV/AIDS) MODELS; IMMUNE RESPONSE; IMMUNE SYSTEMS; INFECTED CELLS; INFECTED PATIENTS; INFECTION DYNAMICS; KEY COMPONENTS; LONG-TERM NONPROGRESSOR; TWO STATE;

BIOLOGICAL SYSTEMS; DRUG THERAPY; DYNAMICS; IMMUNOLOGY; PHILOSOPHICAL ASPECTS; SCHEDULING;

DISEASE CONTROL;

EID: 64049100947     PISSN: 15455955     EISSN: None     Source Type: Journal    
DOI: 10.1109/TASE.2008.2008156     Document Type: Article

References (43)

1. K. Alcorn, A. Poppa, and M. Nicholson, HIV and AIDS Treatments Directory, 16th ed. London, U.K.:NAM, 1999, National AIDS Manual.
2. R. Goldsby, T. Kiudt, B. Osborae, and J. Kuby, Immunology, 5th ed. New York: W. H. Freeman, 2003.
3. M. Sande and P. Volberding, The Medical Management of AIDS, 6th ed. Oxford, U.K.: W. B. Saunders, 1999.
4. UNAIDS/WHO, AIDS Epidemic UNAIDS. Geneva, Switzerland, Dec. 2006, Update.
5. C. Hoffmann, J. Rockstroh, and B. Kamps, HIV Medicine 2006. Paris, France: Flying Publisher, 2006.
6. H. Ortega and M. Martin-Landrove, "A model for continuously mutant HIV-1," in Proc. 22nd Annu. EMBS Int. Conf., 2000, pp. 1917-1920.
7. H. Altes, D. Price, and V. Jansen, "Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV," Vaccine, vol. 20, pp. 3-6, 2002.
8. A. Perelson and P. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," SIAM Review, vol. 41, no. 1, pp. 3-44, 1999.
9. M. Nowak and R. May, Virus Dynamics. Oxford, U.K.: Oxford Univ. Press, 2000.
10. S.Kubiak, H. Lehr,R. Levy, T. Moeller,A. Parker, and E. Swim, "Modeling control of HIV infection through structured treatment interruptions with recommendations for experimental protocol," (CRSC-TR01- 27), Tech. Rep., 2001.
11. S. Blower, H. Gershengorn, and R. Grant, "A tale of two futures: HIV and antiretroviral therapy in San Francisco," Science, vol. 287, pp. 650-654, 2000.
12. A. Asachenkov, G. Marchuk, R. Mohler, and S. Zuev, Disease Dynamics. Cambridge, MA: Birkhauser, 1994.
13. I. Craig and X. Xia, "Can HIV/AIDS be controlled?," IEEE Control Syst. Mag., vol. 25, pp. 80-83, Feb. 2005.
14. L. Wein, S. Zenios, and M. Nowak, "Dynamic multidrug therapies for HIV: A control theoretic approach," J. Theoretical Biology, vol. 185, pp. 15-29, 1997.
15. J. F. de Souza, M. Caetano, and T. Yoneyama, "Optimal control theory applied to the anti-viral treatment of AIDS," in Proc. Conf. Decision Control, 2000, pp. 4839-4844.
16. U. Ledzewicz and H. Schattler, "On optimal controls for a general mathematical model for chemotherapy of HIV," in Proc. Amer. Control Conf., 2002, pp. 3454-3459.
17. D. Kirschner, S. Lenhart, and S. Serbin, "Optimal control of the chemotherapy of HIV," J. Math. Biol., vol. 35, pp. 775-792, 1997.
18. J. Kutch and P. Gurfil, "Optimal control of HIV infection with a continuously- mutating viral population," in Proc. Amer. Control Conf., 2002 ,pp. 4033-4038.
19. M. Brandt and G. Chen, "Feedback control of a biodynamical model of HIV-1," IEEE Trans. Biomed. Eng., vol. 48, no. 7, pp. 754-759, 2001.
20. D. Wodarz and M. Nowak, "Specific therapy regimes could lead to long-term immunological control of HIV," Proc. Nat. Acad. Sci., vol. 96, no. 25, pp. 14 464-14 469, 1999.
21. D. Wodarz, "Helper-dependent vs. helper-independent CTL responses in HIV infection: Implications for drug therapy and resistance," J. Theoretical Biol., vol. 213, pp. 447-459, 2001.
22. D.Wodarz and M. Nowak, "Mathematical models of HIV pathogenesis and treatment," BioEssays, vol. 24, pp. 1178-1187, 2002.
23. B. Adams, H. Banks, M. Davidian, H. Kwon, H. Tran, S. Wynne, and E. Rosenberg, "HIV dynamics: Modeling, data analysis, and optimal treatment protocols," J. Comp. Appl. Math., vol. 184, pp. 10-49, 2005.
24. R. Zurakowski and A. Teel, "Enhancing immune response to HIV infection using MPC-based treatment scheduling," in Proc. Amer. Control Conf., 2003, pp. 1182-1187.
25. R. Zurakowski and A. Teel, "A model predictive control based scheduling method for HIV therapy," J. Theoretical Biol., vol. 238, pp. 368-382, 2006.
26. R. Zurakowski, "Exploiting immune response dynamics in HIV therapy," Ph.D. dissertation, Univ. California, Santa Barbara, CA, 2004.
27. H. Shim, S. Han, I. Jeong, C. Chung, S. Nam, and J. Seo, "Optimal scheduling of drug treatment for HIV infection: Continuous dose control and receding horizon control," Int. J. Control Autom. Syst., vol. 1, no. 3, pp. 282-288, 2003.
28. H. Chang, N. Jo, and H. Shim, "An applicationn of gradual reduction of drug dose to HIV infection model in consideration of drug resistance and drug dose," in Proc. SICE-ICASE Int. Joint Conf., 2006, pp. 5236-5241.
29. B. Adams, H. Banks, H. Kwon, and H. Tran, "Dynamic multidrug therapies for HIV: Optimal and STI control approaches," Math. Biosci. Eng., vol. 1, pp. 223-241, 2004.
30. H. Banks, H. Kwon, J. Toivanen, and H. Tran, "A state-dependent Riccati equation-based estimator approach for HIV feedback contol," Optim. Control Appl. Meth., vol. 27, pp. 93-121, 2006.
31. R. Stengel, R. Ghigliazza, N. Kulkarni, and O. Laplace, "Optimal control of a viral disease," in Proc. Amer. Control Conf., 2001, pp. 3795-3800.
32. R. Stengel, R. Ghigliazza, N. Kulkarni, and O. Laplace, "Optimal control of innate immune response," Opt. Contr. Appl. Methods, vol. 23, pp. 91-104, 2002.
33. R. Stengel, R. Ghigliazza, and N. Kulkarni, "Optimal enhancement of immune response," Bioinformatics, vol. 18, pp. 1227-1235, 2002.
34. H. Chang, N. Jo, and H. Shim, "Gradual reduction of drug dosage on an HIV infection model with helper-independent CTL," J. Control, Autom. Syst. Eng., vol. 10, no. 12, pp. 1148-1154, 2004.
35. D. Ho, A. Neumann, A. Perelson, W. Chen, J. Leonard, and M. Markowitz, "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," Nature, vol. 373, pp. 123-126, 1995.
36. X. Xia and C. Moog, "Identifiability of nonlinear systems with applications to HIV/AIDS models," IEEE Trans. Automat. Control, vol. 48, no. 2, pp. 330-336, 2003.
37. H. Chang and A. Astolfi, "Control of HIV infection dynamics: Approximating high-order dynamics by adapting reduced-order model parameters," IEEE Control Syst. Mag., vol. 28, pp. 28-39, Apr. 2008.
38. H. Chang and A. Astolfi, "Control of the HIV infection dynamics with a reduced second order model," in Proc. Amer. Control Conf., 2007, pp. 4083-4088.
39. D. Callaway and A. Perelson, "HIV-1 infection and low steady state viral loads," Bull. Math. Biol., vol. 64, pp. 29-64, 2001.
40. S. Bonhoeffer, M. Rembiszewski, G. Ortiz, and D. Nixon, "Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection," AIDS, vol. 14, pp. 2313-2322, 2000.
41. A. M. Jeffrey, X. Xia, and I. K. Craig, "When to initiate HIV therapy: A control theoretic approach," IEEE Trans. Biomed. Eng., vol. 50, no. 11, pp. 1213-1220, 2003.
42. X. Zheng, S. Wise, and V. Cristini, "Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite- element/level-set method," Bull. Math. Biol., vol. 67, pp. 211-259, 2005.
43. S. Sanga, J. Sinek, H. Frieboes, M. Ferrari, J. Fruehauf, and V. Cristini, "Mathematical modeling of cancer progression and response to chemotherapy: Towards the development of a multiscale computer simulator," Expert Rev. Anticancer Ther., vol. 6, no. 10, pp. 1361-1376, 2006.